$0.45
-0.02(-3.40%)
Mkt Cap $32M
$0.39
$2.88
52-Week Range
At A Glance
1
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity.
2
Most recently: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment o (2026-01-06).
$32M
Market Cap
—
Revenue
—
Net Income
Employees107
Fundamentals
How The Business Makes Money
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001572616
ISINUS35168W1036
CUSIP35168W103
Phone781-902-8800
Address17 Hartwell Avenue, Lexington, MA, 02421, US
SEC EDGAR